(VERU) Veru Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VERU) Veru Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Veru Inc. BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation decisions. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Enobosarm Phase III metastatic breast cancer
Enobosarm is Veru Inc.'s late-stage asset in AR+ ER+ HER2- metastatic breast cancer, and its Phase III status makes it one of the company’s highest-value programs as of FY2025. The program targets a large, high-need oncology niche with no approved AR-directed therapy in this setting. A positive readout could turn Enobosarm into Veru’s first major oncology revenue line.
Enobosarm plus abemaciclib Phase III
Enobosarm plus abemaciclib Phase III sits in a biomarker-defined breast cancer niche with clear clinical fit. Abemaciclib is already proven, with Lilly reporting $5.3 billion in 2024 sales, which strengthens the combo’s market credibility. That makes this one of Veru Inc.’s strongest near-commercial Star assets.
Sabizabulin plus Enobosarm Phase II triple-negative breast cancer
Triple-negative breast cancer is only about 10% to 15% of breast cancers, but it has fewer targeted options and a high unmet need. Sabizabulin plus Enobosarm gives Veru Inc. a broader shot beyond one breast cancer subtype. If Phase II data are strong, this could shift from an early pipeline bet to a premium growth asset.
Sabizabulin Phase IIb metastatic breast cancer
Sabizabulin’s Phase IIb metastatic breast cancer program sits near the top of Veru Inc.’s pipeline because it is still in active clinical development and aimed at a large oncology market. The program also uses biomarker selection, which can sharpen patient targeting and improve trial readout quality. That makes it one of Veru Inc.’s stronger star candidates.
- Phase IIb = high development value
- Large breast cancer market
- Biomarker fit improves targeting
VERU-100 Phase II prostate cancer
VERU-100 sits in a large prostate cancer pool: the American Cancer Society estimates 313,780 new U.S. cases and 35,770 deaths in 2025. As a Phase II peptide GnRH antagonist given by injection, it targets advanced hormone-sensitive prostate cancer with a differentiated ADT profile. If clinical data hold, it has real Star potential in Veru Inc.'s BCG mix.
- Large, proven prostate cancer market
- Phase II risk still high
- Differentiated injectable GnRH antagonist
Veru’s FY2025 Stars: Enobosarm Leads, VERU-100 Adds Prostate Upside
Veru Inc.’s Stars are led by Enobosarm, a Phase III AR+ ER+ HER2- metastatic breast cancer asset with the clearest near-term value in FY2025. Sabizabulin plus Enobosarm and Sabizabulin Phase IIb in metastatic breast cancer add biomarker-driven upside. VERU-100 also stands out in prostate cancer, a 2025 U.S. market with 313,780 new cases and 35,770 deaths.
| Asset | FY2025 Star signal |
|---|---|
| Enobosarm | Phase III, highest value |
| Sabizabulin combo | Biomarker-driven upside |
| VERU-100 | Large prostate market |
What is included in the product
Detailed Word Document
Veru Inc. BCG Matrix maps its portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page Veru Inc. BCG Matrix clarifying pipeline quadrants for quick strategy decisions
Reference Sources
Veru Inc. Reference Sources provide a clear, traceable evidence trail that boosts credibility and speeds informed decision-making.
Cash Cows
FC2 internal condom
FC2 internal condom is Veru Inc.'s only established commercial product, so it remains the clearest cash generator in the portfolio. It is FDA-approved to help prevent pregnancy and reduce the risk of sexually transmitted infections, giving it a steady niche demand base. In FY2025, FC2 was still the core revenue source while Veru's other programs stayed in development or restructuring.
FC2 government health department sales
Veru Inc.'s FC2 government health department sales fit a Cash Cow because public-sector procurement can recur through established health programs, not speculative R&D. In the 2025 reporting cycle, this kind of demand is usually steadier than launch-driven sales, so it helps fund the business. That makes FC2 a mature, cash-producing line with lower growth but better revenue visibility.
FC2 UN organization sales
UN-linked procurement keeps FC2 in global health programs, where the condom is already accepted and widely distributed. Veru has kept commercialization light, so incremental promotion stays low and cash use is more efficient. That makes FC2 a cash cow in FY2025, even as companywide sales stayed under pressure.
FC2 non-profit entity sales
FC2 non-profit entity sales fit the Cash Cows box because they serve steady institutional demand and the product is mature, so growth is limited. Veru Inc. has kept the model focused on cash generation, not rapid expansion, with FC2 remaining a long-running contributor in FY2025 rather than a high-growth driver.
- Steady non-profit institutional demand
- Mature product, low growth need
- Cash-first, not scale-first model
FC2 commercial distributor sales
FC2’s commercial distributor channel is classic cash-cow behavior: the brand is mature, so Veru Inc. can widen market reach without heavy launch spend. FC2 has been sold for more than 20 years, which keeps commercialization costs lower than for new products and supports steadier margin capture.
- Wide distributor reach across markets
- Mature brand, lower selling costs
- Stable cash generation profile
FC2 Powers Veru’s FY2025 Cash Cow Story
FC2 is Veru Inc.'s clear Cash Cow in FY2025: it is the only established product, sells through government, UN-linked, nonprofit, and distributor channels, and needs limited commercial spend. That maturity supports steadier cash generation even while companywide sales stayed under pressure.
| Cash Cow signal | FY2025 data point |
|---|---|
| Commercial product base | FC2 only |
| Channel mix | Gov, UN, nonprofit, distributors |
| Growth profile | Mature, low-growth |
Preview the Actual Deliverable
Veru Inc. Reference Sources
The Veru Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. There’s no demo version or placeholder content—just the full, ready-to-use report. What you preview is what gets delivered, formatted for immediate use in analysis, presentations, or planning.
Dogs
No approved oncology product revenue
As of fiscal 2025, Veru Inc. still had no approved or marketed oncology product, so oncology revenue was $0 and market share stayed at zero.
That means no oncology product cash flow to fund growth, which fits BCG "Dogs" territory rather than a real winner.
In BCG terms, the line remains a drag on capital and attention.
No approved COVID-19 therapy
Veru had no approved SARS-CoV-2 therapy by end-2025, so this program stayed a Dogs asset in the BCG matrix. Demand also faded after the acute pandemic, when the COVID-19 market shifted from emergency use to a much smaller, more selective niche. With no durable commercial traction, the asset offered little chance to scale revenue or protect value.
No approved hot-flash therapy
Veru Inc.'s hot-flash program, enobosarm, stayed investigational in FY2025 and had no FDA approval. With no commercial launch, it generated no approved product base and no measurable market share, so the return profile stays weak. That makes it a clear Dogs asset in the BCG Matrix.
No approved BPH or LUTS therapy
By end-2025, Veru Inc. still had no approved BPH or LUTS therapy, so this stays a non-revenue asset in a mature market. BPH is huge but crowded: symptoms affect about 50% of men by age 50 and up to 90% by age 80, with cheap generics already dominant. Without FDA approval, the unit remains a cash sink, not a growth driver.
- No approved product by end-2025
- Mature, generic-heavy BPH market
- Zero sales, continued R&D burn
No second commercial brand beyond FC2
Veru Inc. has no second meaningful commercial brand beyond FC2, so the portfolio remains highly concentrated. In FY2025, FC2 still carried the company’s marketed revenue base, while the rest of the pipeline stayed clinical and generated no product sales. That makes diversification weak and leaves the group under dog-like pressure: one brand must fund the business while the rest still need trial success.
- FC2 is the only marketed brand.
- Pipeline assets are still clinical-only.
- Revenue concentration stays very high.
- Weak diversification raises dog risk.
Veru’s Non-FC2 Pipeline Remains a Cash-Burning Dog in FY2025
In fiscal 2025, Veru Inc.'s non-FC2 pipeline still had no approved oncology, COVID-19, BPH/LUTS, or enobosarm product, so each stayed at $0 revenue and 0 market share. FC2 remained the only real sales engine, which leaves the rest of the portfolio in Dogs territory because it burns cash without commercial pull.
| Asset | FY2025 | BCG view |
|---|---|---|
| Oncology | $0 revenue | Dog |
| COVID-19 | No approved sale | Dog |
| Enobosarm | Investigational only | Dog |
| BPH/LUTS | No approval | Dog |
Question Marks
Sabizabulin Phase II metastatic castration and ARTA-resistant prostate cancer
Sabizabulin in metastatic castration and ARTA-resistant prostate cancer sits in a huge oncology market, but Veru Inc. still has zero commercial share here. The program is only in Phase II, so it must show clear benefit versus existing AR-targeted therapy options before it can matter. This is a Question Mark: high upside, but it needs more R&D spend and strong data to move beyond an early-stage asset.
Sabizabulin Phase III SARS-CoV-2 high-risk patients
Sabizabulin is an advanced Phase III program, but Veru Inc. still has 0 approved COVID-19 therapies, so the asset has no commercial share yet. The COVID-19 market had cooled hard by end-2025, which makes the program more of a high-uncertainty Question Mark than a proven cash driver. Its value rests on clinical readout risk, not current sales.
Zuclomiphene citrate Phase II hot flashes
Zuclomiphene citrate for hot flashes sits in Question Marks: menopausal vasomotor symptoms affect millions, but Veru Inc.'s program is still Phase II and has no commercial sales yet. The return case is unclear because clinical proof is early, and Veru’s FY2025 filings still reflect an unproven, pre-revenue asset.
Lower urinary tract symptoms enlarged prostate formulation
BPH/LUTS is a huge but crowded market: about 50% of men 51–60 and up to 90% over 80 have BPH symptoms. Veru Inc.’s enlarged-prostate formulation is still uncommercialized, so it sits in Question Marks until it proves efficacy, tolerability, and real market fit in 2025/2026 data.
That means high upside, but also high risk: without clear clinical wins and a commercial path, it stays a cash drain in a mature category.
- Large demand
- Heavy competition
- No commercialization yet
- Needs clinical proof
Sabizabulin plus Enobosarm metastatic triple-negative breast cancer
Sabizabulin plus enobosarm in metastatic triple-negative breast cancer is still early-stage and has no commercial market share, so it sits in Veru Inc.'s invest-or-walk-away zone. TNBC is only about 10%-15% of breast cancers, but metastatic disease remains hard to treat and the 5-year relative survival is about 32% overall for breast cancer and much lower once it spreads.
- High unmet need
- Investigational only
- No revenue or share yet
- High upside, high risk
Veru’s High-Risk Pipeline Needs Late-Stage Proof
Veru Inc.’s Question Marks are all pre-revenue or low-share assets with big market upside but no clear 2025/2026 commercial proof. Sabizabulin, zuclomiphene citrate, BPH/LUTS, and sabizabulin plus enobosarm all need stronger late-stage data before they can move out of this high-risk bucket.
| Asset | Status | Signal |
|---|---|---|
| Sabizabulin | Phase II/III | No sales |
| Zuclomiphene | Phase II | No sales |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.